Final planned overall survival (OS) from OPTiM, a randomized Phase III trial of talimogene laherparepvec (T-VEC) versus GM-CSF for the treatment of unresected stage IIIB/C/IV melanoma (NCT00769704). (6th November 2014)

Record Type:: Journal Article
Title:: Final planned overall survival (OS) from OPTiM, a randomized Phase III trial of talimogene laherparepvec (T-VEC) versus GM-CSF for the treatment of unresected stage IIIB/C/IV melanoma (NCT00769704). (6th November 2014)
Main Title:: Final planned overall survival (OS) from OPTiM, a randomized Phase III trial of talimogene laherparepvec (T-VEC) versus GM-CSF for the treatment of unresected stage IIIB/C/IV melanoma (NCT00769704)
Authors:: Andtbacka, Robert HI
Collichio, Frances A
Amatruda, Thomas
Senzer, Neil
Chesney, Jason
Delman, Keith
Spitler, Lynn
Puzanov, Igor
Agarwala, Sanjiv
Milhem, Mohammed
Harrington, Kevin
Middleton, Mark
Li, Ai
Shilkrut, Mark
Coffin, Robert
Kaufman, Howard
Abstract:
Is Part Of:: Journal for immunotherapy of cancer. Volume 2(2014)Supplement 3
Journal:: Journal for immunotherapy of cancer
Issue:: Volume 2(2014)Supplement 3
Issue Display:: Volume 2, Issue 3 (2014)
Year:: 2014
Volume:: 2
Issue:: 3
Issue Sort Value:: 2014-0002-0003-0000
Page Start:
Page End:
Publication Date:: 2014-11-06
Subjects:: Melanoma -- Overall Survival -- Herpes Simplex -- Antitumor Immune Response -- ECOG Performance Status
Cancer -- Immunotherapy -- Periodicals
Cancer -- Immunological aspects -- Periodicals
Tumors -- Immunological aspects -- Periodicals
Immunotherapy -- Periodicals
616.99406105
Journal URLs:: http://www.immunotherapyofcancer.org ↗
https://jitc.bmj.com/ ↗
http://link.springer.com/ ↗
DOI:: 10.1186/2051-1426-2-S3-P263 ↗
Languages:: English
ISSNs:: 2051-1426
Deposit Type:: Legaldeposit
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗
Physical Locations:: British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store
Ingest File:: 19840.xml